Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: Comparison with conventional treatment for refractory disease

Journal of Clinical Gastroenterology

Volumn 39, Issue 9, 2005, Pages 819-825

  Czaja, Albert J ^a   Carpenter, Herschel A ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

Autoimmune hepatitis; Mycophenolate mofetil; Treatment failure

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PURINE ANTAGONIST; TACROLIMUS; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; EVALUATION; FEMALE; FIBROSIS; HEPATITIS; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT FAILURE;

ADRENAL CORTEX HORMONES; ADULT; ASPARTATE AMINOTRANSFERASES; AZATHIOPRINE; BILIRUBIN; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLOBULINS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 25444468309     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000177260.72692.e8     Document Type: Article

References (44)

1. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis. 2002;22:365-377.
2. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-497.
3. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207-215.
4. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890-897.
5. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371-375.
6. Adams A, Gish R, Wakil E, et al. Mycophenolate mofetil improves liver tests in patients with autoimmune hepatitis (AIH). (abstract) Hepatology. 2003;38(suppl 1):490A.
7. Devlin SM, Swain MG, Urbanski SJ, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol. 2004;18:321-326.
8. Brunt EM, Di Bisceglie AM. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum Pathol. 2004;35:509-512.
9. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 2000;95:1201-1207.
10. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis. 2000;6:16-20.
11. Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000;343:1156-1162.
12. Jones EA, Ten Kate FJW, Ter Borg F, et al. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 1999;11:1165-1169.
13. Jones EA. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. Hepatology. 2002;35:258-262.
14. Altschuler EL. Mycophenolate mofetil for primary biliary cirrhosis and sclerosing cholangitis? Nephrol Dial Transplant. 1999;14:798-799.
15. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 1993;11(suppl.8):S117-S119.
16. Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. QJM. 2000;93:15-20.
17. Ferraris JR, Tambutti ML, Redal MA, et al. Conversion from azathioprine to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation. 2000;70:297-301.
18. Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. QJM. 2000;93:15-20.
19. Jain AB, Hamad I, Rakela J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998;68:1395-1398.
20. Becker BN. Mycophenolate mofetil. Transplant Proc. 1999;31:2777-2778.
21. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
22. Cohn RG, Mirkovich A, Dunlap B, et al. Mycophenolate acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation. 1999;68:411-418.
23. Mehling A, Grabbe S, Voskort M. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165:2374-2381.
24. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
25. Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976;8:221-227.
26. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
27. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824-1832.
28. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology. 2004;39:1631-1638.
29. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988;8:781-784.
30. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958-963.
31. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448-453.
32. Vierling J. Autoimmune liver disease. Action Plan for Liver Disease Research. [National Institute of Diabetes and Digestive and Liver Diseases Web site]. August 23, 2004. Available at: www.niddk.nih.gov/fund/divisions/ddn/ldrb/ topics.htm. Accessed December 2, 2004.
33. Person JL, McHutchison JG, Fong TL, et al. A case of cyclosporine- sensitive, steroid resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol. 1993;17:317-320.
34. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol. 1994;21:1040-1047.
35. Jackson LD. Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36:459-461.
36. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999;30:222-227.
37. Fernandes NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241-248.
38. Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J, et al. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321-1327.
39. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996;110:271-274.
40. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771-776.
41. Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol. 1997;35:571-578.
42. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol. 1998;29:990-993.
43. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585-590.
44. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:490-495.